Literature DB >> 12161285

Intracellular delivery of monoclonal antibodies.

Bi-Xing Chen1, Bernard F Erlanger.   

Abstract

With some exceptions, antibodies do not have the ability to penetrate cell membranes and act intracellularly. Their usefulness in research and medicine would be considerably enhanced if they had the intrinsic ability to act on intracellular targets. We report here that covalently linking poly-L-arginine (average molecular weight 10750, ca. 68 residues) to the oligosaccharide moiety of the CH2 region of an immunoglobulin makes possible penetration into the cytoplasm and, and in some cases into the nucleus of cells. We demonstrate this with five antibodies and seven cell lines. Retention of specificity is demonstrated by ELISA with an anti-HIV Gag antibody and intracellularly with a monoclonal anti-tubulin antibody. As the antibodies are covalently modified, they have the potential to be used in intact animals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161285     DOI: 10.1016/s0165-2478(02)00146-3

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  6 in total

Review 1.  Targeting antibodies to the cytoplasm.

Authors:  Andrea L J Marschall; André Frenzel; Thomas Schirrmann; Manuela Schüngel; Stefan Dübel
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

Review 2.  Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives.

Authors:  Leena N Patel; Jennica L Zaro; Wei-Chiang Shen
Journal:  Pharm Res       Date:  2007-04-19       Impact factor: 4.200

3.  An effective cell-penetrating antibody delivery platform.

Authors:  Andreas Herrmann; Toshikage Nagao; Chunyan Zhang; Christoph Lahtz; Yi-Jia Li; Chanyu Yue; Ronja Mülfarth; Hua Yu
Journal:  JCI Insight       Date:  2019-07-25

Review 4.  Targeted Intracellular Delivery of Antibodies: The State of the Art.

Authors:  Tatiana A Slastnikova; A V Ulasov; A A Rosenkranz; A S Sobolev
Journal:  Front Pharmacol       Date:  2018-10-24       Impact factor: 5.810

5.  Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond.

Authors:  V V Oberemok; O A Andreeva; K V Laikova; I A Novikov; A V Kubyshkin
Journal:  Inflamm Res       Date:  2022-05-06       Impact factor: 6.986

Review 6.  Intracellular targeting with engineered proteins.

Authors:  Shane Miersch; Sachdev S Sidhu
Journal:  F1000Res       Date:  2016-08-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.